Healthcare Business

Protect Your Dogs and Cats From These Fall Poisons

Most dog and cat owners know they shouldn’t feed their pets things like chocolate, nuts, and salty snack foods, and may be aware that plants like tulips and azaleas can ...
Read Full Story »

Is This Epilepsy Cannabinoid Treatment Really in Trouble?

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) shares dropped on Wednesday after the firm announced results from its midstage epilepsy trial. Specifically, the top-line results are from the Phase 2 Believe 1 ...
Read Full Story »

Will This Ebola Vaccine Be the Next Big Thing?

NewLink Genetics Corp. (NASDAQ: NLNK) shares jumped on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has accepted Merck & Co.’s (NYSE: MRK) Biologics License ...
Read Full Story »

Even More Implied Analyst Upside for Karyopharm Therapeutics After Royalty Pact

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) posted a solid gain on Monday despite the pressure in the broader markets. It turns out that biotech and emerging health stocks can surge on ...
Read Full Story »

Good News, Bad News in the War on Peanut Allergy

Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares dipped on Monday after the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food and Drug Administration (FDA) voted to support the use ...
Read Full Story »

Are Alder Shareholders Getting Enough in the Buyout?

Alder BioPharmaceuticals Inc. (NASDAQ: ALDR) shares skyrocketed on Monday after the firm announced that Lundbeck would acquire it. The transaction is valued at up to $1.95 billion net of cash ...
Read Full Story »

How Old Is Too Old to Be President? Medical Experts Weigh In

As the current group of Democratic candidates has several candidates who are over 70 years old, and President Donald Trump is 73, experts writing for the JAMA Network, a group ...
Read Full Story »

7 Biotechs With Catalysts in the Next Month

If there is one area that can generate riches for speculative investors, it would have to be biotech and emerging pharmaceuticals. After all, how many companies can go from nothing ...
Read Full Story »

FDA Gets Off the Pot for IBS Treatment Approval

Ardelyx Inc. (NASDAQ: ARDX) shares dropped sharply on Friday after the firm announced that the U.S. Food and Drug Administration (FDA) has approved its treatment of irritable bowel syndrome with ...
Read Full Story »

SmileDirectClub Fails to Impress in IPO

SmileDirectClub Inc. (NASDAQ: SDC) shares dropped on Thursday in its IPO. Shares entered the market at $20.55, well below the pricing of the offering at $23 per share. The company ...
Read Full Story »

10X Genomics Enters the Market With a Bang

10X Genomics Inc. (NASDAQ: TXG) shares entered the market with a bang on Thursday. Its initial public offering went off at $54, well above the anticipated price of $39. The ...
Read Full Story »

Does This Macular Degeneration Study Deserve More Credit?

Adverum Biotechnologies Inc. (NASDAQ: ADVM) shares dropped sharply on Thursday after the firm announced data from its Optic Phase 1 clinical trial in wet age-related macular degeneration (wet AMD). This ...
Read Full Story »

Major Biotechs Scare Off Short Sellers

The short interest data are out for the most recent settlement date, August 30. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

What’s Left After Lexicon’s Terminated Partnership With Sanofi

Lexicon Pharmaceuticals Inc.'s (NASDAQ: LXRX) shares made a huge gain on Wednesday after the announcement that its alliance with Sanofi (NASDAQ: SNY) was terminated. The partnership was centered around the ...
Read Full Story »